Agilent

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agilent and other ETFs, options, and stocks.

About A

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. 

CEO
Padraig Mcdonnell
CEOPadraig Mcdonnell
Employees
18,100
Employees18,100
Headquarters
Santa Clara, California
HeadquartersSanta Clara, California
Founded
1999
Founded1999
Employees
18,100
Employees18,100

A Key Statistics

Market cap
41.64B
Market cap41.64B
Price-Earnings ratio
27.34
Price-Earnings ratio27.34
Dividend yield
0.74%
Dividend yield0.74%
Average volume
2.40M
Average volume2.40M
High today
$142.42
High today$142.42
Low today
$138.20
Low today$138.20
Open price
$139.17
Open price$139.17
Volume
2.28M
Volume2.28M
52 Week high
$160.27
52 Week high$160.27
52 Week low
$108.35
52 Week low$108.35

Stock Snapshot

With a market cap of 41.64B, Agilent(A) trades at $139.50. The stock has a price-to-earnings ratio of 27.34 and currently yields dividends of 0.74%.

During the trading session on 2026-07-29, Agilent(A) shares reached a daily high of $142.42 and a low of $138.20. At a current price of $139.50, the stock is +0.9% higher than the low and still -2.1% under the high.

Trading activity shows a volume of 2.28M, compared to an average daily volume of 2.4M.

The stock's 52-week range extends from a low of $108.35 to a high of $160.27.

The stock's 52-week range extends from a low of $108.35 to a high of $160.27.

A News

MarketWatch 13h
Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

...

Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Simply Wall St 21h
Agilent Technologies Could Be 14% Undervalued Following FDA Cancer Test Approval

Agilent Technologies (A) stock is in focus after the company received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay, a compani...

Agilent Technologies Could Be 14% Undervalued Following FDA Cancer Test Approval
Simply Wall St 3d
Agilent Technologies Is Up 5.4% After New OPDIVO-Linked PD-L1 Test Approval - Has The Bull Case Changed?

In July 2026, Agilent Technologies received U.S. FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several g...

Agilent Technologies Is Up 5.4% After New OPDIVO-Linked PD-L1 Test Approval - Has The Bull Case Changed?

Analyst ratings

75%

of 24 ratings
Buy
75%
Hold
25%
Sell
0%

More A News

Simply Wall St 4d
Agilent Stock May Be 22% Below Fair Value As HALO Investment Grows

Agilent Technologies stock has delivered a 16.2% return over the past year, yet there is a clear split in what the valuation tools are saying, with a Discounted...

Agilent Stock May Be 22% Below Fair Value As HALO Investment Grows

People also own

Based on the portfolios of people who own A. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.